Insecticides India Ltd

The transcript does not mention any current or future plans for fundraising through debt or equity for Insecticides (India) Limited. Key points related to financial strategy include: - Focus on improving working capital and cash flow management. - Emphasis on operational efficiencies, margin improvement, and manufacturing expansions funded through internal planning. - No specific discussion or indication of raising funds via debt or equity during the call. - The company is engaging professionals and investing in R&D, plant expansion, and marketing from existing resources. - Inventory levels are being managed carefully, with some expected increase due to new season preparations, but no mention of external fundraising to support this. In summary, there is no disclosed plan for debt or equity fundraising as per the current conference call transcript.

- Insecticides (India) Limited is undertaking multiple expansions: - Formulation expansion at Dahej facility. - New manufacturing facility planned in SEZ. - Expansion of plant at Sotanala. - Company is increasing technical manufacturing capacity, with focus on both Dahej (herbicides) and Chopanki (insecticides). - Discussions underway with global companies for possible CRAMS (Contract Research and Manufacturing Services) collaborations and other activities. - Continuous efforts on backward integration to improve margins by manufacturing from basic levels. - New leadership hired to professionally manage manufacturing, expansions, and supply chain, aiming to support growth and efficiency. - Ongoing R&D investments for new patented and generic active ingredients (AIs) and formulation development. - Emphasis on capacity enhancement and automation for sustainable operations at R&D centers in Dahej and Chopanki.

- Targeting double-digit growth, with expectation to recover and meet year-end targets despite a slow H1 growth of ~4%. (Page 13) - For Focus Maharatna and Maharatna products, volume growth was flat in the quarter, but recovery and growth expected in H2. (Page 15) - B2C volumes were flat in the recent quarter; growth is driven by B2B and international business. (Page 15) - Export business expected to grow; aiming to reach Rs. 150 crore sales in exports this year. (Page 12) - Increasing the share of own captive technicals in product portfolio from ~50% to over 65% now, aiming to cross 70% in the next 2-3 years, to improve margins and growth. (Page 11) - New product launches planned, focusing on innovative AIs and specialty herbicides for continuous scaling and better margins (~35%+ targeted). (Pages 11-12) - Positive outlook for H2 sales driven by good monsoon, increased Rabi season sowing, and full reservoirs enabling higher crop sowing. (Page 14-15)

- Management targets double-digit and strong double-digit growth for Focus Maharatna and Maharatna products in FY'26. - First half of FY'26 showed ~4% growth; expects significant recovery in second half to meet targets. - Technical segment will see new Active Ingredients (AIs) launches, typically 3-4 per year, aiming for gross margins above 35%. - Margins on new products targeted at Maharatna or Focus Maharatna levels; some patented molecules may exceed 50%. - Export growth expected to be positive, targeting Rs 150 crore in exports for FY'26. - EBITDA margin hovered at 13% in H1 FY'26, with management confident of sustaining or improving this margin level going forward. - Profit after tax (PAT) affected by financial costs and market conditions but expected to improve with increased innovation and market activities. - Continuous cost management and premium product mix focus aim to boost operating profits and EPS in coming years.

- Export side order book is complete till March 2026 with fresh orders still coming in month-wise. - For B2B segment, orders are seasonal and current order book includes fresh orders for November and December (Rabi season started). - Orders for the last quarter (Q4) will begin to be taken after some time; not currently open. - Export business shows positive growth expectations, aiming to achieve around Rs. 150 crore sales in the near term. - Overall, order inflow is healthy with export order book secured and B2B orders ongoing per seasonality.